USNA Add to watchlist $18.30 0.54 (-2.87%) Last updated: May 31, 2026 21:49
52-Week Range
$18.30
$16.60 $18.30 $38.32

Fundamentals Overview

USANA Health Sciences, Inc. is near the low of its 52-week range with premium valuation, trending downward today.

Valuation premium

P/E 38 P/B 0.62 P/S 0.36

Intrinsic value (DCF)

+402% upside vs price

Profitability

Net margin 1%

Risk (Beta)

0.77 — lower vol

Earnings & growth

EPS $0.48 Rev +10.6% Profit +523.4% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 54% confidence Risk: Lower Volatility — Beta 0.77. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +402% upside vs price · Analyst grade: A-

Pressures (Sell):

Sentiment weakening (8 downgrades) · 3M vs S&P 500: -23.1% · 3M vs Consumer Defensive sector: -17.2%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$337.87M
P/E (TTM)
37.97
EPS (TTM)
$0.48
Dividend Yield
N/A
52-Week Range
$16.60 - $38.32
Volume vs Avg
N/A
Beta
0.77

About

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, sna...
Sector: Consumer Defensive
Headquarters: US
Employees: 1,700
IPO Date: Apr 1994
Website: www.usana.com
Beta: 0.77 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A-. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 7, Hold: 4, Neutral: 18, Underperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $91.86; current price is $18.30. That’s a +402% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 37.97
DCF value (model) $91.86 (402% upside)
PEG (TTM) N/A
P/B (TTM) 0.62
P/S (TTM) 0.36
P/FCF (TTM) 114.11
Liquidity & enterprise
Current Ratio (TTM) 2.51
Quick Ratio (TTM) 1.69
Cash Ratio (TTM) 1.39
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 0.96%
Gross margin (TTM) 76.72%
Operating margin (TTM) 5.3%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for USNA.

Analyst Sentiment at a Glance

A- Sentiment Weakening
Buy 7Hold 4Neutral 18Underperform 1
2 upgrades, 8 downgrades
Consensus Target
$35.00
High Target
$35.00
Low Target
$35.00
Median Target
$35.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
DA Davidson maintain Neutral Neutral 2025-02-27
DA Davidson maintain Neutral Neutral 2025-01-02
DA Davidson maintain Neutral Neutral 2024-10-23
DA Davidson maintain Neutral Neutral 2024-07-25
DA Davidson maintain Neutral Neutral 2024-05-07
DA Davidson maintain Neutral Neutral 2024-02-22
DA Davidson maintain Neutral Neutral 2023-10-25
DA Davidson maintain Neutral Neutral 2023-04-26
DA Davidson maintain Neutral Neutral 2023-02-13
DA Davidson maintain Neutral Neutral 2022-10-27
DA Davidson maintain Neutral Neutral 2022-07-28
DA Davidson maintain Neutral Neutral 2022-07-12
Jefferies downgrade Hold Underperform 2022-07-07
DA Davidson maintain Neutral Neutral 2022-04-27
DA Davidson maintain Neutral Neutral 2022-04-14
Roth Capital maintain Buy Buy 2021-02-10
Roth Capital maintain Buy Buy 2020-12-17
Jefferies maintain Hold Hold 2019-08-22
Sidoti & Co. downgrade Buy Neutral 2019-07-03
Tigress Financial maintain Buy Buy 2019-04-16
Pivotal Research downgrade Buy Hold 2018-04-23
Sidoti & Co. downgrade Buy Neutral 2018-01-24
Pivotal Research upgrade Hold Buy 2017-05-03
Pivotal Research downgrade Buy Hold 2017-05-01
DA Davidson downgrade Buy Neutral 2016-02-10
DA Davidson upgrade Neutral Buy 2015-09-16
DA Davidson downgrade Buy Neutral 2015-08-06
DA Davidson maintain Buy Buy 2015-06-26
Pivotal Research downgrade Buy Hold 2015-04-27
Pivotal Research maintain Buy Buy 2014-10-20